Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention
Canadian Journal of Cardiology2015Vol. 32(6), pp. 747–753
Citations Over TimeTop 10% of 2015 papers
Jason G. Andrade, Andrew D. Krahn, Allan C. Skanes, Daniel M. Purdham, Antonio Ciaccia, Sean P. Connors
Abstract
Real-world prescriptions do not reflect reported values, which suggests that other factors influence patient-physician decision-making around OAC therapy. Data on self-reported adherence to OAC therapy and discordance in the use of OACs from prescribed regimens are concerning and warrant further investigation.
Related Papers
- Warfarin and epistaxis: should warfarin always be discontinued?(1997)
- → Potential Interaction Between Azithromycin and Warfarin(1999)37 cited
- → Trends in warfarin use and its associations with thromboembolic and bleeding rates in a population with atrial fibrillation between 1996 and 2011(2018)16 cited
- → Drug Interactions and Risk of Bleeding among Patients with Atrial Fibrillation (AF) Discharged with Warfarin(2006)1 cited
- → Adjusted-dose warfarin for atrial fibrillation reduced stroke risk better than low-dose warfarin plus aspirin(1997)